Polymer coatings and delayed arterial healing following drug-eluting stent implantation

Minerva Cardioangiologica

Volumn 57, Issue 5, 2009, Pages 567-584

  Byrne, R A ^a   Joner, M ^a   Kastrati, A ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Absorbable implants; Autopsy; Coronary restenosis; Drug evaluation; Drug eluting stents; Polymers; Thrombosis

Indexed keywords

BIOLIMUS A9; BIOMATRIX FLEX; CELLULOSE; ENDEAVOR; ESTROGEN; EVEROLIMUS; EXCEL; FIBRIN; HYDROXYAPATITE; IMMUNOSUPPRESSIVE AGENT; ISAR; LATEX; MAHOROBA; METHACRYLIC ACID; NEVO; NOBORI; PACLITAXEL; PIMECROLIMUS; POLYACRYLIC ACID; POLYESTER; POLYETHYLENE; POLYGLACTIN; POLYLACTIC ACID; POLYLACTIDE; POLYMER; POLYSTYRENE; PROBUCOL; RAPAMYCIN; SHELLAC; UNCLASSIFIED DRUG; ZOTAROLIMUS;

ARTERY INTIMA PROLIFERATION; ATHEROSCLEROSIS; CORONARY STENT; DELAYED ARTERIAL HEALING; DRUG ELUTING STENT; DRUG RELEASE; EOSINOPHIL; FIBRIN DEPOSITION; FOOD AND DRUG ADMINISTRATION; HEALING IMPAIRMENT; HUMAN; INFLAMMATION; INFLAMMATORY INFILTRATE; NONHUMAN; RESTENOSIS; REVIEW; STENT THROMBOSIS; ANIMAL; ARTERY; PROSTHESIS; TIME; WOUND HEALING;

ANIMALS; ARTERIES; CORONARY RESTENOSIS; DRUG-ELUTING STENTS; HUMANS; POLYMERS; PROSTHESIS DESIGN; TIME FACTORS; WOUND HEALING;

EID: 77449133793     PISSN: 00264725     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (100)

1. Puel J, Joffre F, Rousseau H, Guermonprez JL, Lancelin B, Morice MC et al. [Self-expanding coronary endoprosthesis in the prevention of restenosis following transluminal angioplasty. Preliminary clinical study]. Arch Mal Coeur Vaiss 1987;80:1311-2.
2. Sigwart U, Puel J, Mirkovitch V, Joffre F, Kappenberger L. Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. N Engl J Med 1987;316:701-6.
3. Fischman DL, Leon MB, Baim DS, Schatz RA, Savage MP, Penn I et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med 1994;331:496-501.
4. Serruys PW, de Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med 1994;331:489-95.
5. Costa MA, Simon DI. Molecular basis of restenosis and drug-eluting stents. Circulation 2005;111:2257-73.
6. Kastrati A, Mehilli J, Dirschinger J, Dotzer F, Schuhlen H, Neumann FJ et al. Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO) trial. Circulation 2001;103:2816-21.
7. Pache J, Dibra A, Mehilli J, Dirschinger J, Schomig A, Kastrati A. Drug-eluting stents compared with thinstrut bare stents for the reduction of restenosis: a prospective, randomized trial. Eur Heart J 2005;26:1262-8.
8. Pache J, Kastrati A, Mehilli J, Schuhlen H, Dotzer F, Hausleiter J et al. Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO-2) trial. J Am Coll Cardiol 2003;41:1283-8.
9. Byrne RA, Sarafoff N, Kastrati A, Schomig A. Drug-eluting stents in percutaneous coronary intervention: a benefit-risk assessment. Drug Saf 2009;32:749-70.
10. Wessely R, Schömig A, Kastrati A. Sirolimus and Paclitaxel on polymer-based drug-eluting stents: similar but different. J Am Coll Cardiol 2006;47:708-14.
11. Byrne RA, Iijima R, Mehilli J, Pinieck S, Bruskina O, Schomig A et al. Durability of antirestenotic efficacy in drug-eluting stents with and without permanent polymer. JACC Cardiovasc Interv 2009;2:291-9.
12. Finn AV, Nakazawa G, Kolodgie FD, Virmani R. Temporal course of neointimal formation after drug-eluting stent placement: is our understanding of restenosis changing? JACC Cardiovasc Interv 2009;2:300-2.
13. Kastrati A, Mehilli J, Pache J, Kaiser C, Valgimigli M, Kelbaek H et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 2007;356:1030-9.
14. Stone GW, Moses JW, Ellis SG, Schofer J, Dawkins KD, Morice MC et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 2007;356:998-1008.
15. Tamai H, Igaki K, Kyo E, Kosuga K, Kawashima A, Matsui S et al. Initial and 6-month results of biodegradable poly-1-lactic acid coronary stents in humans. Circulation 2000;102:399-404.
16. Serruys PW, Ormiston JA, Onuma Y, Regar E, Gonzalo N, Garcia-Garcia HM et al. A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. Lancet 2009;373:897-910.
17. Klugherz BD, Llanos G, Lieuallen W, Kopia GA, Papandreou G, Narayan P et al. Twenty-eight-day efficacy and phamacokinetics of the sirolimus-eluting stent. Coron Artery Dis 2002;13:183-8.
18. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002;346:1773-80.
19. Kamath KR, Barry JJ, Miller KM. The Taxus drug-eluting stent: a new paradigm in controlled drug delivery. Adv Drug Deliv Rev 2006;58:412-36.
20. Kandzari DE, Leon MB. Overview of pharmacology and clinical trials program with the zotarolimus-eluting endeavor stent. J Interv Cardiol 2006;19:405-13.
21. Beijk MA, Piek JJ. XIENCE V everolimus-eluting coronary stent system: a novel second generation drug-eluting stent. Expert Rev Med Devices 2007;4:11-21.
22. Kukreja N, Onuma Y, Serruys PW. Xience V everolimus-eluting coronary stent. Expert Rev Med Devices 2009;6:219-29.
23. Sousa JE, Costa MA, Abizaid A, Abizaid AS, Feres F, Pinto IM et al. Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: a quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation 2001;103:192-5.
24. Sousa JE, Costa MA, Abizaid A, Feres F, Seixas AC, Tanajura LF et al. Four-year angiographic and intravascular ultrasound follow-up of patients treated with sirolimus-eluting stents. Circulation 2005;111:2326-9.
25. Sousa JE, Costa MA, Abizaid AC, Rensing BJ, Abizaid AS, Tanajura LF et al. Sustained suppression of neointimal proliferation by sirolimus-eluting stents: one-year angiographic and intravascular ultrasound follow-up. Circulation 2001;104:2007-11.
26. Costa JR, Jr., Abizaid A, Costa R, Feres F, Tanajura LF, Maldonado G et al. 1-year results of the hydroxyapatite polymer-free sirolimus-eluting stent for the treatment of single de novo coronary lesions: the VESTASYNC I trial. JACC Cardiovasc Interv 2009;2:422-7.
27. Chamié D, Costa J, Abizaid A, Almiro da Silva J, Feres F, Mattos L et al. Sirolimus-Eluting Stents With and Without Polymeric Coating: Serial Angiography and Three-dimensional Intravascular Ultrasound Analysis. Rev Bras Cardiol Invas 2009;17:20-30.
28. Mehilli J, Byrne RA, Wieczorek A, Iijima R, Schulz S, Bruskina O et al. Randomized trial of three rapamycin-eluting stents with different coating strategies for the reduction of coronary restenosis. Eur Heart J 2008;29:1975-82.
29. Byrne RA, Mehilli J, Iijima R, Schulz S, Pache J, Seyfarth M et al. A polymer-free dual drug-eluting stent in patients with coronary artery disease: a randomized trial vs. polymer-based drug-eluting stents. Eur Heart J 2009;30:923-31.
30. Kastrati A. Clinical and Angiographic Results from the Permanent Polymer DES Arm of the ISAR-TEST 4 Randomized Trial: Subgroup Analysis of Cypher vs. Xience in 1304 Patients. In: Transcatheter Cardiovascular Therapeutics; San Francisco; 2009 (Abstract)
31. Colombo A, Drzewiecki J, Banning A, Grube E, Hauptmann K, Silber S et al. Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation 2003;108:788-94.
32. Serruys PW, Sianos G, Abizaid A, Aoki J, den Heijer P, Bonnier H et al. The effect of variable dose and release kinetics on neointimal hyperplasia using a novel paclitaxel-eluting stent platform: the Paclitaxel In-Stent Controlled Elution Study (PISCES). J Am Coll Cardiol 2005;46:253-60.
33. Lansky AJ, Costa RA, Mintz GS, Tsuchiya Y, Midei M, Cox DA et al. Non-polymer-based paclitaxel-coated coronary stents for the treatment of patients with de novo coronary lesions: angiographic follow-up of the DEUVER clinical trial. Circulation 2004;109:1948-54.
34. Hwang CW, Edelman ER. Arterial ultrastructure influences transport of locally delivered drugs. Circ Res 2002;90:826-32.
35. Hwang CW, Wu D, Edelman ER. Physiological transport forces govern drug distribution for stent-based delivery. Circulation 2001;104:600-5.
36. Hwang CW, Wu D, Edelman ER. Impact of transport and drug properties on the local pharmacology of drug-eluting stents. Int J Cardiovasc Intervent 2003;5:7-12.
37. Ribichini F, Joner M, Ferrero V, Finn AV, Crimins J, Nakazawa G et al. Effects of oral prednisone after stenting in a rabbit model of established atherosclerosis. J Am Coll Cardiol 2007;50:176-85.
38. Steigerwald K, Merl S, Kastrati A, Wieczorek A, Vorpahl M, Mannhold R et al. The pre-clinical assessment of rapamycin-eluting, durable polymer-free stent coating concepts. Biomaterials 2009;30:632-7.
39. Togni M, Windecker S, Meier B. Treatment of Restenosis. Curr Interv Cardiol Rep 2001;3:306-310.
40. Meier B. My vision of interventional cardiology - today and tomorrow. In: EuroPCR; 2009; Paris; 2009.
41. Gruberg L, Waksman R. Intravascular radiation for the prevention of recurrence of restenosis in coronary arteries. Expert Opin Investig Drugs 2001;10:891-907.
42. Crocker I, Robinson KA. Rationale for coronary artery radiation therapy. Semin Radiat Oncol 2002;12:3-16.
43. Serruys PW. ARTS I - the rapamycin eluting stent; ARTS II - the rosy prophecy. Eur Heart J 2002;23:757-9.
44. Camenzind E, Steg PG, Wijns W. Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern. Circulation 2007;115:1440-55; discussion 1455.
45. Pfisterer M, Brunner-La Rocca HP, Buser PT, Rickenbacher P, Hunziker P, Mueller C et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol 2006;48:2584-91.
46. Guagliumi G, Farb A, Musumeci G, Valsecchi O, Tespili M, Motta T et al. Images in cardiovascular medicine. Sirolimus-eluting stent implanted in human coronary artery for 16 months: pathological findings. Circulation 2003;107:1340-1.
47. Virmani R, Guagliumi G, Farb A, Musumeci G, Grieco N, Motta T et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation 2004;109:701-5.
48. Virmani R, Kolodgie FD, Farb A, Lafont A. Drug eluting stents: are human and animal studies comparable? Heart 2003;89:133-8.
49. Mauri L, Hsieh WH, Massaro JM, Ho KK, D'Agostino R, Cutlip DE. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 2007;356:1020-9.
50. Stettler C, Wandel S, Allemann S, Kastrati A, Morice MC, Schömig A et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet 2007;370:937-48.
51. Matsumoto D, Shite J, Shinke T, Otake H, Tanino Y, Ogasawara D et al. Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography. Eur Heart J 2007;28:961-7.
52. Gonzalo N, Serruys PW, Regar E. Optical coherence tomography: clinical applications and the evaluation of DES. Minerva Cardioangiol 2008;56:511-25.
53. Guagliumi G, Costa M. From a foggy sight to a clear vision. JACC Cardiovasc Interv 2009;2:467-9.
54. Kotani J, Awata M, Nanto S, Uematsu M, Oshima F, Minamiguchi H et al. Incomplete neointimal coverage of sirolimus-eluting stents: angioscopic findings. J Am Coll Cardiol 2006;47:2108-11.
55. van der Giessen WJ, Lincoff AM, Schwartz RS, van Beusekom HM, Serruys PW, Holmes DR, Jr. et al. Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. Circulation 1996;94:1690-7.
56. Virmani R, Farb A, Guagliumi G, Kolodgie FD. Drug-eluting stents: caution and concerns for long-term outcome. Coron Artery Dis 2004;15:313-8.
57. Suzuki T, Kopia G, Hayashi S, Bailey LR, Llanos G, Wilensky R et al. Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model. Circulation 2001;104:1188-93.
58. Carter AJ, Aggarwal M, Kopia GA, Tio F, Tsao PS, Kolata R et al. Long-term effects of polymer-based, slow-release, sirolimus-eluting stents in a porcine coronary model. Cardiovasc Res 2004;63:617-24.
59. Finn AV, Nakazawa G, Joner M, Kolodgie FD, Mont EK, Gold HK et al. Vascular responses to drug eluting stents: importance of delayed healing. Arterioscler Thromb Vasc Biol 2007;27:1500-10.
60. Wilson GJ, Nakazawa G, Schwartz RS, Huibregtse B, Poff B, Herbst TJ et al. Comparison of inflammatory response after implantation of sirolimus- and paclitaxel-eluting stents in porcine coronary arteries. Circulation 2009;120:141-9, 1-2.
61. Drachmen DE, Edelman ER, Seifert P, Groothuis AR, Bornstein DA, Kamath KR et al. Neointimal thickening after stent delivery of paclitaxel: change in composition and arrest of growth over six months. J Am Coll Cardiol 2000;36:2325-32.
62. Farb A, Heller PF, Shroff S, Cheng L, Kolodgie FD, Carter AJ et al. Pathological analysis of local delivery of paclitaxel via a polymer-coated stent. Circulation 2001;104:473-9.
63. Heldman AW, Cheng L, Jenkins GM, Heller PF, Kim DW, Ware M, Jr. et at. Paclitaxel stent coating inhibits neointimal hyperplasia at 4 weeks in a porcine model of coronary restenosis. Circulation 2001;103:2289-95.
64. Scheller B, Grandt A, Wnendt S, Lorenz G, Bohm M, Nickenig G. Comparative study of tacrolimus and paclitaxel stent coating in the porcine coronary model. Z Kardiol 2005;94:445-52.
65. Goode J. FDA Summary: Taxus express paclitaxel-eluting monorail and over-the-wire coronary stent systems - PMA for markting approval. U.S. Food and Drug Administration 2003;23.
66. Finn AV, Kolodgie FD, Harnek J, Guerrero LJ, Acampado E, Tefera K et al. Differential response of delayed healing and persistent inflammation at sites of overlapping sirolimus- or paclitaxel-eluting stents. Circulation 2005;112:270-8.
67. Carter AJ, Brodeur A, Collingwood R, Ross S, Gibson L, Wang CA et al. Experimental efficacy of an everolimus eluting cobalt chromium stent. Catheter Cardiovasc Interv 2006;68:97-103.
68. Garcia-Touchard A, Burke SE, Toner JL, Cromack K, Schwartz RS. Zotarolimus-eluting stents reduce experimental coronary artery neointimal hyperplasia after 4 weeks. Eur Heart J 2006;27:988-93.
69. Collingwood R, Gibson L, Sedlik S, Virmani R, Carter AJ. Stent-based delivery of ABT-578 via a phosphorylcholine surface coating reduces neointimal formation in the porcine coronary model. Catheter Cardiovasc Interv 2005;65:227-32.
70. Nakazawa G, Finn AV, John MC, Kolodgie FD, Virmani R. The significance of preclinical evaluation of sirolimus-, paclitaxel-, and zotarolimus-eluting stents. Am J Cardiol 2007;100:36M-44M.
71. Joner M, Nakazawa G, Finn AV, Quee SC, Coleman L, Acampado E et al. Endothelial cell recovery between comparator polymer-based drug-eluting stents. J Am Coll Cardiol 2008;52:333-42.
72. Suzuki Y, Yeung AC, Ikeno F. The pre-clinical animal model in the translational research of interventional cardiology. JACC Cardiovasc Interv 2009;2:373-83.
73. Pound P, Ebrahim S, Sandercock P, Bracken MB, Roberts I. Where is the evidence that animal research benefits humans? BMJ 2004;328:514-7.
74. Perel P, Roberts I, Sena E, Wheble P, Briscoe C, Sandercock P et al. Comparison of treatment effects between animal experiments and clinical trials: systematic review. BMJ 2007;334:197.
75. Hwang CW, Levin AD, Jonas M, Li PH, Edelman ER. Thrombosis modulates arterial drug distribution for drug-eluting stents. Circulation 2005;111:1619-26. (Pubitemid 40525161)
76. Levin AD, Vukmirovic N, Hwang CW, Edelman ER. Specific binding to intracellular proteins determines arterial transport properties for rapamycin and paclitaxel. Proc Natl Acad Sci U S A 2004;101:9463-7. (Pubitemid 38812897)
77. Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 2006;48:193-202: (Pubitemid 43929240)
78. Nebeker JR, Virmani R, Bennett CL, Hoffman JM, Samore MH, Alvarez J et al. Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project. J Am Coll Cardiol 2006;47:175-81.
79. Cook S, Ladich E, Nakazawa G, Eshtehardi P, Neidhart M, Vogel R et al. Correlation of intravascular ultrasound findings with histopathological analysis of thrombus aspirates in patients with very late drug-eluting stent thrombosis. Circulation 2009;120:391-9.
80. Grewe PH, Deneke T, Machraoui A, Barmeyer J, Muller KM. Acute and chronic tissue response to coronary stent implantation: pathologic findings in human specimen. J Am Coll Cardiol 2000;35:157-63. (Pubitemid 30061274)
81. Kastrati A, Schomig A, Dietz R, Neumann FJ, Richardt G. Time course of restenosis during the first year after emergency coronary stenting. Circulation 1993;87:1498-505. (Pubitemid 23133093)
82. Kimura T, Yokoi H, Nakagawa Y, Tamura T, Kaburagi S, Sawada Y et al. Three-year follow-up after implantation of metallic coronary-artery stents. N Engl J Med 1996;334:561-6. (Pubitemid 26066129)
83. Byrne RA, Kufner S, Tiroch K, Massberg S, Laugwitz KL, Birkmeier A et al. Randomised trial of three rapamycin-eluting stents with different coating strategies for the reduction of coronary restenosis: 2-year follow-up results. Heart 2009;95:1489-94.
84. Krucoff MW, Kereiakes DJ, Petersen JL, Mehran R, Hasselblad V, Lansky AJ et al. A novel bioresorbable polymer paclitaxel-eluting stent for the treatment of single and multivessel coronary disease: primary results of the COSTAR (Cobalt Chromium Stent With Antiproliferative for Restenosis) II study. J Am Coll Cardiol 2008;51:1543-52.
85. Mehilli J, Kastrati A, Wessely R, Dibra A, Hausleiter J, Jaschke B et al. Randomized trial of a nonpolymerbased rapamycin-eluting stent versus a polymer-based paclitaxel-eluting stent for the reduction of late lumen loss. Circulation 2006;113:273-9. (Pubitemid 43754385)
86. Adriaenssens T, Mehilli J, Wessely R, Ndrepepa G, Seyfarth M, Wieczorek A et al. Does addition of estradiol improve the efficacy of a rapamycin-eluting stent? Results of the ISAR-PEACE randomized trial. J Am Coll Cardiol 2007;49:1265-71. (Pubitemid 46476843)
87. Verheye S, Agostoni P, Dawkins KD, Dens J, Rutsch W, Carrie D et al. The GENESIS (Randomized, Multicenter Study of the Pimecrolimus-Eluting and Pimecrolimus/Paclitaxel-Eluting Coronary Stent System in Patients with De Novo Lesions of the Native Coronary Arteries) trial. JACC Cardiovasc Interv 2009;2:205-14.
88. Niemela KO. Biodegradable coating for drug-eluting stents - more than a facelift? Eur Heart J 2008;29: 1930-1.
89. Commandeur S, van Beusekom HM, van der Giessen WJ. Polymers, drug release, and drug-eluting stents. J Interv Cardiol 2006;19:500-6. (Pubitemid 44722241)
90. Han Y, Jing Q, Xu B, Yang L, Liu H, Shang X et al. Safety and efficacy of biodegradable polymer-coated sirolimus-eluting stents in "real-world" practice: 18-month clinical and 9-month angiographic outcomes. JACC Cardiovasc Interv 2009;2:303-9.
91. Byrne RA, Kastrati A, Kufner S, Massberg S, Birkmeier KA, Laugwitz KL etal. Randomized, non-inferiority trial of three limus agent-eluting stents with different polymer coatings: the Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents (ISAR-TEST-4) Trial. Eur Heart J 2009.
92. Windecker S, Serruys PW, Wandel S, Buszman P, Trznadel S, Linke A et al. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial. Lancet 2008;372:1163-73.
93. Onuma Y, Serruys P, den Heijer P, Joesoef KS, Duckers H, Regar E et al. MAHOROBA, first-in-man study: 6-month results of a biodegradable polymer sustained release tacrolimus-eluting stent in de novo coronary stenoses. Eur Heart J 2009;30:1477-85.
94. Spaulding C. Six-month results of the NEVO RES Elution-1 (RES-1) trial. In: EuroPCR; 2009; Barcelona; 2009.
95. Chevalier B, Silber S, Park SJ, Garcia E, Schuler G, Suryapranata H et al. Randomized Comparison of the Nobori Biolimus A9-Eluting Coronary Stent With the Taxus Liberté Paclitaxel-Eluting Coronary Stent in Patients With Stenosis in Native Coronary Arteries. The NOBORI 1 Trial - Phase 2. Circulation: Cardiovascular Interventions 2009;2:188-195.
96. Alt E, Haehnel I, Beilharz C, Prietzel K, Preter D, Stemberger A et al. Inhibition of neointima formation after experimental coronary artery stenting: a new biodegradable stent coating releasing hirudin and the prostacyclin analogue iloprost. Circulation 2000;101: 1453-8.
97. Jabara R, Chronos N, Robinson K. Novel bioabsorbable salicylate-based polymer as a drug-eluting stent coating. Catheter Cardiovasc Interv 2008;72:186-94.
98. Wildemann B, Sander A, Schwabe P, Lucke M, Stockle U, Raschke M et al. Short term in vivo biocompatibility testing of biodegradable poly(D,L-lactide) - growth factor coating for orthopaedic implants. Biomaterials 2005;26:4035-40.
99. De Jong WH, Eelco Bergsma J, Robinson JE, Bos RR. Tissue response to partially in vitro predegraded polyL-lactide implants. Biomaterials 2005;26:1781-91.
100. Lineoff AM, Furst JG, Ellis SG, Tuch RJ, Topol EJ. Sustained local delivery of dexamethasone by a novel intravascular eluting stent to prevent restenosis in the porcine coronary injury model. J Am Coll Cardiol 1997;29:808-16.